Overview

• A July 31 study in the Journal of the American Chemical Society is the first to synthesize and evaluate each pure stereoisomer of ionizable lipid ALC-315 in lipid nanoparticles
• Cell survival and GFP expression assays reveal that the (S,S) stereoisomer sustains mRNA delivery efficiency of the standard mixture while significantly reducing cellular toxicity
• Dr. Chandra Kanta De and colleagues demonstrate that stereochemistry directly governs both the efficacy and safety profiles of LNP formulations
• ALC-315’s established role in the Pfizer/BioNTech COVID-19 vaccine highlights the impact of optimized ionizable lipids on pandemic vaccines and future mRNA therapies
• Support from the Max Planck Society, DFG, ERC, JSPS and AMED will drive refinement of LNP design for gene therapies, personalized cancer vaccines and other mRNA-based treatments